Gennex Laboratories Ltd.
Snapshot View

10.21 -0.48 ▼-4.5%

26 July 2021, 04:00:00 P.M.
Volume: 858,522

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website
Financial Indicators
Market Cap 129.16 Cr.
Earnings per share (EPS) 0.32 Trailing Twelve Months Ending 2021-03
Price-Earning Ratio (PE) 31.99 Trailing Twelve Months Ending 2021-03
Industry PE 35.25 Trailing Twelve Months Ending 2021-03
Book Value / Share 3.14 Trailing Twelve Months Ending 2021-03
Price to Book Value 3.25 Calculated using Price: 10.21
Dividend Yield 0.00 Period Ending 2020-03
No. of Shares Subscribed 12.65 Cr. 126,503,000 Shares
FaceValue 1
Company Profile

Gennex Laboratories (formerly Prudential Pharmaceuticals) is a public limited company established in the year 1995 and has been engaged in the manufacturing of bulk drugs and intermediates. The company started as one of the leading manufacturer and exporter of bulk drugs and intermediates. Quality is the strength of the company and major part of its finished products are exported to various countries viz. Germany, United Kingdom, Spain, Singapore, Canada, Switzerland, Iran, Bangladesh, Pakistan and other major countries. Gennex Laboratories has diversified its activities to biotech products in order to have better prospects and opportunities for the company for expanding its bussiness activities and to meet the marketing requirements.

The company had commenced its commercial operations of Guaifenesin in November, 1995 and in a span of about one and half years, it was able to capture about 70% of the domestic market mainly due to the impeccable quality, aggressive marketing strategies, cost effective manufacturing and efficient distribution cum market penetration. It has also established itself fairly well in the export market and recognized well by many end-users and trading giants of international market.

The company has catered to countries like USA, Mexico, Spain and Germany and the quality has been accepted and appreciated extremely well with all the customers. Several customers have evinced interest on long-term tie-ups. Slowly but surely, the company is constantly expanding its reach to USA and European markets and it has been receiving very encouraging enquiries from prospective customers based on quality recommendations by existing customers. The company’s headquarters is situated in the heart of the city and the factory is situated at Survey No 133, IDA Bollaram, Jinnaram Mandal, Medak District-502 325, Andhra Pradesh, India. The factory occupies a total land area of 8,000 square meters. The total building floor space is1,945 square meters. The storage space is 500 square meters. The central lab has a floor space of 225 square meters.

Products of the company:

  • Guaiphenesin
  • Methocarbamol
  • Fluconazole
  • Phenazopyridine

Certification:

  • Gennex Laboratories is an ISO 9001: 2008 approved company and obtained GMP Certification from the Central Drug Authority.
  • The company is also planning for ISO 14001: 2002 certification and OHSHAS 18000 to ensure its products are more widely accepted in the international market.

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
-4.49%
1 Week
-6.24%
1 Month
+13.70%
3 Month
+33.99%
6 Month
+110.08%
1 Year
+135.25%
2 Year
+196.80%
5 Year
+58.05%
4 years 2017-03 2018-03 2019-03 2020-03
Return on Equity (%) 8.74 2.67 6.77 5.34
Return on Capital Employed (%) 10.91 6.31 10.52 8.36
Return on Assets (%) 5.50 1.68 4.35 3.42

Balance Sheet View Details

Particulars 4 years 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Shh. Funds 31 32 34 36
Non Curr. Liab. 1 1 1 0
Curr. Liab. 17 18 17 21
Minority Int.
Equity & Liab. 49 50 52 57
Non Curr. Assets 23 23 23 22
Curr. Assets 26 28 29 35
Misc. Exp. not W/O
Total Assets 49 50 52 57

Profit Loss View Details

Particulars 4 years 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Net Sales 42 44 56 56
Other Income 0 1 1 1
Total Income 42 45 57 57
Total Expenditure -37 -42 -52 -52
PBIDT 5 3 5 4
Interest -1 -1 -1 -1
Depreciation -1 -1 -1 -1
Taxation 0 -1 -1 -1
Exceptional Items 0 0
PAT 3 1 2 2

Cash Flow View Details

Particulars 4 years 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Cash Fr. Operatn. 0 3 2 -2
Cash Fr. Inv. -1 -1 -1 0
Cash Fr. Finan. 1 -2 1 0
Net Change 0 0 2 -2
Cash & Cash Eqvt 1 1 3 1

Shareholding Pattern View Details

9 Qtrs 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%)
Promoter 22.05 22.05 22.05 22.05 22.05 22.05 22.05 22.05 22.05
Public 77.95 77.95 77.95 77.95 77.95 77.95 77.95 77.95 77.95
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Fri, 23 Jul 2021
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
With reference to the captioned subject matter pursuant to regulation 74(5) of SEBI (Depositories and Participants) Regulations 2018 we hereby submit the certificate received from the M/s. R&D Infotech Private Limited Registrar and Transfer Agent of the Company for the Quarter ended June 30 2021.

We request you to take the above information on record and acknowledge the receipt of the same.
Tue, 20 Jul 2021
Shareholding for the Period Ended June 30 2021
Gennex Laboratories Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30 2021. For more details kindly Click here
Mon, 19 Jul 2021
Statement Of Investor Complaints For The Quarter Ended June 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter
0000
Name of the Signatory :- RAJESH VANKADARA
Designation :- Company Secretary and Compliance Officer

Technical Scans View Details

Mon, 26 Jul 2021
Strongly Outperforming Benchmark Index Strongly Outperforming Benchmark Index
Decreasing Relative Strength - Benchmark index Decreasing Relative Strength - Benchmark index
Strongly Outperforming Sectoral Index Strongly Outperforming Sectoral Index
Both SRS And ARS Above Zero Both SRS And ARS Above Zero
Close Crossing 20 EMA From Above Close Crossing 20 EMA From Above

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 168,769.22 703.40 +1.4%
Divi's Laboratories Ltd. 130,349.05 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. 90,021.63 5,411.25 -0.2%
Cipla Ltd. 76,675.40 950.55 +0.3%
Cadila Healthcare Ltd. 61,992.73 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. 58,965.37 4,100.95 +4.7%
Aurobindo Pharma Ltd. 55,837.02 952.95 -1.1%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 58.12 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2021-03 65.69 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 46.13 5,411.25 -0.2%
Cipla Ltd. Consolidated 2021-03 31.88 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 29.06 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 392.16 4,100.95 +4.7%
Aurobindo Pharma Ltd. Consolidated 2021-03 10.47 952.95 -1.1%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 3.63 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2021-03 14.02 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 5.14 5,411.25 -0.2%
Cipla Ltd. Consolidated 2021-03 4.18 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 4.77 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.83 4,100.95 +4.7%
Aurobindo Pharma Ltd. Consolidated 2021-03 2.55 952.95 -1.1%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2020-03 0.00 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 5,411.25 -0.2%
Cipla Ltd. Consolidated 2020-03 0.18 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 4,100.95 +4.7%
Aurobindo Pharma Ltd. Consolidated 2020-03 0.33 952.95 -1.1%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2020-03 19.30 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 5,411.25 -0.2%
Cipla Ltd. Consolidated 2020-03 10.09 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 4,100.95 +4.7%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.53 952.95 -1.1%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2020-03 25.36 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 5,411.25 -0.2%
Cipla Ltd. Consolidated 2020-03 12.53 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 4,100.95 +4.7%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.80 952.95 -1.1%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2020-03 5,394.42 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 5,411.25 -0.2%
Cipla Ltd. Consolidated 2020-03 17,131.99 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 4,100.95 +4.7%
Aurobindo Pharma Ltd. Consolidated 2020-03 23,098.51 952.95 -1.1%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2020-03 1,376.54 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 5,411.25 -0.2%
Cipla Ltd. Consolidated 2020-03 1,546.98 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 4,100.95 +4.7%
Aurobindo Pharma Ltd. Consolidated 2020-03 2,844.69 952.95 -1.1%